2022
An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, Bhagwagar Z, Braeuninger S, Mortberg A, Olsen K, Gastón Schäfer S, Walter C, Seifried E, Wikman A, Kjeldsen-Kragh J, Koehm M. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study. Journal Of Thrombosis And Haemostasis 2022, 21: 838-849. PMID: 36696185, DOI: 10.1016/j.jtha.2022.11.041.Peer-Reviewed Original ResearchConceptsFetal/Neonatal Alloimmune ThrombocytopeniaNeonatal alloimmune thrombocytopeniaHPA-1aAlloimmune thrombocytopeniaHuman platelet antigen 1aTreatment-emergent adverse eventsPlacebo 1 hourHPA-1a antibodiesFNAIT casesHyperimmune IgGPrimary endpointAdverse eventsFetus/Healthy menSingle doseAntigen 1aHLA-A2Concept studyCohort 1PlaceboFlow cytometryThrombocytopeniaPlateletsAdministrationWeeks
1999
Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Whale R, Bhagwagar Z, Cowen P. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology 1999, 145: 223-226. PMID: 10463324, DOI: 10.1007/s002130051052.Peer-Reviewed Original ResearchConceptsPlasma growth hormoneGrowth hormoneCross-over design studyEffect of ketanserinGrowth hormone responsePathophysiology of depressionGrowth hormone releaseNeuroendocrine probeAntidepressant medicationHealthy menReceptor agonistReceptor subtypesHormone releaseHealthy volunteersBlood samplesNeuroendocrine profilePlasma prolactinAgonist activityHormone responseReceptor functionAssay of prolactinZolmitriptanHormoneOral temperatureMode of action